1074 related articles for article (PubMed ID: 8996777)
1. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
[TBL] [Abstract][Full Text] [Related]
2. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
3. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
[TBL] [Abstract][Full Text] [Related]
4. Diagnosing cytomegalovirus disease in CMV seropositive renal allograft recipients: a comparison between the detection of CMV DNAemia by polymerase chain reaction and antigenemia by CMV pp65 assay.
Lo CY; Ho KN; Yuen KY; Lui SL; Li FK; Chan TM; Lo WK; Cheng IK
Clin Transplant; 1997 Aug; 11(4):286-93. PubMed ID: 9267717
[TBL] [Abstract][Full Text] [Related]
5. Cytomegalovirus antigenemia and outcomes of patients undergoing allogeneic peripheral blood stem cell transplantation: effects of long-term high-dose acyclovir prophylaxis and preemptive ganciclovir treatment.
Hazar V; Ugur A; Colak D; Saba R; Tezcan G; Kupesiz A; Karadogan I; Gultekin M; Yesilipek A; Undar L
Jpn J Infect Dis; 2006 Aug; 59(4):216-21. PubMed ID: 16936338
[TBL] [Abstract][Full Text] [Related]
6. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
Murray BM; Subramaniam S
Transpl Infect Dis; 2004 Mar; 6(1):3-9. PubMed ID: 15225220
[TBL] [Abstract][Full Text] [Related]
7. [Cytomegalovirus infection after heart transplantation. Retrospective analysis of an antiviral CMV prevention].
Antretter H; Höfer D; Klaus A; Larcher C; Margreiter J; Margreiter R
Dtsch Med Wochenschr; 2000 Apr; 125(15):445-51. PubMed ID: 10800441
[TBL] [Abstract][Full Text] [Related]
8. Long-term renal graft function and survival in patients with high-risk for cytomegalovirus infection receiving preemptive therapy.
Alberú J; Morales-Buenrostro LE; Correa-Rotter R; Muñoz-Trejo T; Zúñiga-Varga J; Cuéllar-González JV; Mayorga-Madrigal H; Vanegas-Carrero R; Aranda F; Rodríguez-Romo R; Herrera-Garcia C; González-Michaca L; Sierra-Madero JG
Rev Invest Clin; 2008; 60(5):365-74. PubMed ID: 19227433
[TBL] [Abstract][Full Text] [Related]
9. [pp65 antigenemia in evaluation of cytomegalovirus infection after kidney transplantation].
Orlić P; Dvornik S; Husnjak SC; Aralica M; Orlić L; Zivcić-Cosić S; Sladoje-Martinović B; Fućak M
Acta Med Croatica; 2003; 57(1):49-52. PubMed ID: 12876863
[TBL] [Abstract][Full Text] [Related]
10. Cytomegalovirus: occurrence, severity, and effect on graft survival in simultaneous pancreas-kidney transplantation.
Ricart MJ; Malaise J; Moreno A; Crespo M; Fernández-Cruz L;
Nephrol Dial Transplant; 2005 May; 20 Suppl 2():ii25-ii32, ii62. PubMed ID: 15814546
[TBL] [Abstract][Full Text] [Related]
11. A single-center experience with ganciclovir-resistant cytomegalovirus in lung transplant recipients: treatment and outcome.
Reddy AJ; Zaas AK; Hanson KE; Palmer SM
J Heart Lung Transplant; 2007 Dec; 26(12):1286-92. PubMed ID: 18096480
[TBL] [Abstract][Full Text] [Related]
12. Detection of CMV-DNA in peripheral blood leukocytes of liver transplant patients after ganciclovir treatment.
Loginov R; Höckerstedt K; Lautenschlager I
Arch Virol; 2003 Jul; 148(7):1269-74. PubMed ID: 12827460
[TBL] [Abstract][Full Text] [Related]
13. [The significance of risk-adapted antiviral prophylaxis and modern virus diagnosis for organ survival after kidney transplantation].
Fricke L; Steinhoff J; Hartwig-Weber I; Bein G
Dtsch Med Wochenschr; 1997 May; 122(18):565-71. PubMed ID: 9190308
[TBL] [Abstract][Full Text] [Related]
14. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
Winston DJ; Busuttil RW
Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
[TBL] [Abstract][Full Text] [Related]
15. Combination antiviral therapy for ganciclovir-resistant cytomegalovirus infection in solid-organ transplant recipients.
Mylonakis E; Kallas WM; Fishman JA
Clin Infect Dis; 2002 May; 34(10):1337-41. PubMed ID: 11981729
[TBL] [Abstract][Full Text] [Related]
16. Pre-emptive therapy against cytomegalovirus (CMV) disease guided by CMV antigenemia assay after allogeneic hematopoietic stem cell transplantation: a single-center experience in Japan.
Kanda Y; Mineishi S; Saito T; Seo S; Saito A; Suenaga K; Ohnishi M; Niiya H; Nakai K; Takeuchi T; Kawahigashi N; Shoji N; Ogasawara T; Tanosaki R; Kobayashi Y; Tobinai K; Kami M; Mori S; Suzuki R; Kunitoh H; Takaue Y
Bone Marrow Transplant; 2001 Feb; 27(4):437-44. PubMed ID: 11313674
[TBL] [Abstract][Full Text] [Related]
17. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
[TBL] [Abstract][Full Text] [Related]
18. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
19. Early treatment of CMV infections in allogeneic bone marrow transplant recipients with foscarnet or ganciclovir.
Bacigalupo A; van Lint MT; Tedone E; Moro F; Sanna MA; Longren M; Trespi G; Frassoni F; Occhini D; Gualandi F
Bone Marrow Transplant; 1994 Jun; 13(6):753-8. PubMed ID: 7920310
[TBL] [Abstract][Full Text] [Related]
20. CMV antigenemia (the lower matrix protein PP65), a marker for the guidance of antiviral therapy in cytomegalovirus disease after orthotopic heart transplantation.
Iberer F; Tscheliessnigg KH; Halwachs G; Auer T; Wasler A; Petutschnigg B; Müller H; Freigassner M; Allmayr T; Hipmair G
Wien Klin Wochenschr; 1995; 107(23):718-22. PubMed ID: 8560893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
